{
    "clinical_study": {
        "@rank": "149572", 
        "arm_group": [
            {
                "arm_group_label": "Necitumumab + Gem and Cis", 
                "arm_group_type": "Experimental", 
                "description": "Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.\nPhase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
            }, 
            {
                "arm_group_label": "Gemcitabine + Cisplatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles.  Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles ."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the Phase 1b portion of the study is to investigate how the body tolerates\n      necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line\n      treatment in participants with Stage IV squamous NSCLC and to determine the recommended dose\n      for the subsequent Phase 2 portion of the study.\n\n      The purpose of the Phase 2 portion of the study is to evaluate the efficacy of necitumumab\n      in combination with gemcitabine and cisplatin chemotherapy in participants with Stage IV\n      squamous NSCLC in a first-line setting."
        }, 
        "brief_title": "A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Squamous Non-Small Cell Lung Cancer Disease\n\n          -  Clinical Stage IV\n\n          -  Measurable or nonmeasurable disease as defined by Response Evaluation Criteria in\n             Solid Tumors (RECIST) version 1.1\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n\n          -  No prior chemotherapy regimen, surgery and chest radiotherapy\n\n          -  Adequate organ function\n\n          -  Estimated life expectancy of at least 12 weeks\n\n        Exclusion Criteria:\n\n          -  Has undergone major surgery within 28 days prior to enrollment or have planned major\n             surgery, subcutaneous venous access device placement within 7 days prior to\n             enrollment\n\n          -  Has undergone any prior radiation therapy, except for Gamma Knife radiation and\n             palliative radiation treatment at least 14 days have elapsed from last radiation\n             treatment prior to enrollment\n\n          -  Has brain metastases that are symptomatic or require surgery, medication and\n             radiotherapy except Gamma Knife\n\n          -  Has superior vena cava syndrome\n\n          -  Has clinically relevant coronary artery disease or uncontrolled congestive - heart\n             failure\n\n          -  Has uncontrolled hypertension\n\n          -  Has diabetes requiring insulin\n\n          -  Has an angina or has experienced myocardial infarction within 6 months prior to\n             enrollment\n\n          -  Has an Acquired Immunodeficiency Syndrome (AIDS)-related illness\n\n          -  Has evidence of or test positive test results for hepatitis B, or hepatitis C virus\n             antibodies\n\n          -  Has a known allergy and history of hypersensitivity reaction\n\n          -  Has significant third-space fluid retention\n\n          -  Has history of interstitial pneumonitis\n\n          -  Has an ongoing or active infection\n\n          -  Has a history of significant neurological or psychiatric disorders\n\n          -  Has a Grade 2 peripheral neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "189", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763788", 
            "org_study_id": "14461", 
            "secondary_id": "I4X-JE-JFCM"
        }, 
        "intervention": [
            {
                "arm_group_label": "Necitumumab + Gem and Cis", 
                "description": "Administered IV", 
                "intervention_name": "Necitumumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "IMC-11F8", 
                    "LY3012211"
                ]
            }, 
            {
                "arm_group_label": [
                    "Necitumumab + Gem and Cis", 
                    "Gemcitabine + Cisplatin"
                ], 
                "description": "Administered IV", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "LY188011"
            }, 
            {
                "arm_group_label": [
                    "Necitumumab + Gem and Cis", 
                    "Gemcitabine + Cisplatin"
                ], 
                "description": "Administered IV", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan", 
                        "zip": "464-8681"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "277 8577"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Ehime", 
                        "country": "Japan", 
                        "zip": "791-0280"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "830-0011"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "060-8648"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "650-0047"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Ishikawa", 
                        "country": "Japan", 
                        "zip": "920-8641"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan", 
                        "zip": "240-0062"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Miyagi", 
                        "country": "Japan", 
                        "zip": "980-8574"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Nagasaki", 
                        "country": "Japan", 
                        "zip": "852-8501"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Niigata", 
                        "country": "Japan", 
                        "zip": "951-8566"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Oita", 
                        "country": "Japan", 
                        "zip": "8795593"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Okayama", 
                        "country": "Japan", 
                        "zip": "700-8558"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "5918555"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan", 
                        "zip": "362-0806"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan", 
                        "zip": "411-8777"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "135-8550"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Wakayama", 
                        "country": "Japan", 
                        "zip": "641-8510"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Yamaguchi", 
                        "country": "Japan", 
                        "zip": "755-0241"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 21 in Cycle 1 (estimated up to 21 days)"
            }, 
            {
                "measure": "Phase 2: Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Death from Any Cause (estimated up to 39 months)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Phase 2: Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Death from Any Cause (estimated up to 39 months)"
            }, 
            {
                "measure": "Phase 1b: Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease (estimated up to 39 months)"
            }, 
            {
                "measure": "Phase 2: Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease (estimated up to 39 months)"
            }, 
            {
                "measure": "Phase 2: Time to Treatment Failure (TTF)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Death from Disease Any Cause (estimated up to 39 months)"
            }, 
            {
                "measure": "Phase 2: Change from Baseline in EuroQol 5-Dimensional Scale (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease (estimated up to 39 months)"
            }, 
            {
                "measure": "Phase 2: Change from Baseline in Lung Cancer Symptom Scale (LCSS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Participant Stops Study (estimated up to 39 months)"
            }, 
            {
                "measure": "Phase 1b/2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 4 (estimated up to 3 months)"
            }, 
            {
                "measure": "Phase 1b: PK: Cmax of Gemcitabine and Cisplatin", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 1 (estimated up to 1 Month)"
            }, 
            {
                "measure": "Phase 1b: PK: Area Under the Concentration Curve (AUC) of Necitumumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 4 (estimated up to 3 months)"
            }, 
            {
                "measure": "Phase 1b: PK: AUC of Gemcitabine and Cisplatin", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 4 (estimated up to 3 months)"
            }, 
            {
                "measure": "Phase 2:  PK: Minimum Concentration (Ctrough) of Necitumumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Cycle 4 (estimated up to 3 months)"
            }, 
            {
                "measure": "Number of Participants with Anti Necitumumab Antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 30 Days Post Last Infusion (estimated up to 39 months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}